A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects with Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN (Amgen 20170758)
This is a multicenter, prospective, observational cohort study in subjects receiving myelosuppressive chemotherapy for a non-myeloid malignancy and are considered at high risk for developing FN.